Edition:
United States

bluebird bio Inc (BLUE.OQ)

BLUE.OQ on NASDAQ Stock Exchange Global Select Market

130.80USD
20 Sep 2017
Change (% chg)

$0.50 (+0.38%)
Prev Close
$130.30
Open
$130.30
Day's High
$132.95
Day's Low
$128.00
Volume
191,491
Avg. Vol
307,709
52-wk High
$136.85
52-wk Low
$37.05

Latest Key Developments (Source: Significant Developments)

Bluebird Bio Inc initiates ‍expansion cohort of CRB-401 Phase 1 study of bb2121
Wednesday, 13 Sep 2017 08:00am EDT 

Sept 13 (Reuters) - bluebird bio Inc :bluebird bio Inc - ‍expansion cohort of crb-401 phase 1 study of bb2121, an anti-BCMA CAR T therapy, has been initiated​.bluebird bio Inc - ‍bluebird bio and Celgene Corp are jointly developing bb2121​.  Full Article

Bluebird Bio Q2 net loss per share $1.73
Wednesday, 2 Aug 2017 04:05pm EDT 

Aug 2 (Reuters) - Bluebird Bio Inc :Bluebird Bio reports second quarter 2017 financial results and recent operational progress.Q2 revenue $16.7 million versus $1.6 million.Q2 revenue view $5.2 million -- Thomson Reuters I/B/E/S.Bluebird Bio sees that cash, cash equivalents & marketable securities of $1.2 billion as of June 30, 2017 will be sufficient to fund current operations into 2020.Qtrly net loss per share $1.73.Q2 earnings per share view $-1.65 -- Thomson Reuters I/B/E/S.  Full Article

Bluebird Bio announces pricing of public offering of common stock
Tuesday, 27 Jun 2017 06:29pm EDT 

June 27 (Reuters) - Bluebird Bio Inc ::Bluebird Bio announces pricing of public offering of common stock.Bluebird Bio Inc - pricing of an underwritten public offering of 3.8 million shares of its common stock at a public offering price of $105.00 per share.  Full Article

Bluebird bio reports updated clinical data from starbeam study
Monday, 26 Jun 2017 04:17pm EDT 

June 26 (Reuters) - Bluebird Bio Inc -:bluebird bio Inc says on June 26, co reported updated clinical data from starbeam study clinical study of its lenti-d product candidate - sec filing.15/17 patients (88%) in initial study cohort remain free of major functional disabilities (mfds) at 24 months.bluebird bio Inc - in starbeam study, safety profile of lenti-d was consistent with myeloablative conditioning.bluebird bio Inc - no patients treated with lenti-d had graft versus host disease (gvhd), and there was no graft rejection or clonal dominance..  Full Article

Bluebird Bio announces proposed public offering of common stock
Monday, 26 Jun 2017 04:06pm EDT 

June 26 (Reuters) - Bluebird Bio Inc :Bluebird Bio announces proposed public offering of common stock.Bluebird Bio Inc says it has commenced an underwritten public offering of $350 million of its common stock.  Full Article

Bluebird bio Q1 total revenue $6.8 million
Wednesday, 3 May 2017 04:05pm EDT 

May 3 (Reuters) - Bluebird Bio Inc ::Bluebird bio reports first quarter 2017 financial results and recent operational progress.Qtrly net loss per share - basic and diluted $ 1.68.Qtrly total revenue $ 6.8 million versus $ 1.5 million.Q1 earnings per share view $-1.78, revenue view $2.1 million -- Thomson Reuters I/B/E/S.Bluebird Bio Inc- ended quarter with $799.9 million in cash, cash equivalents and marketable securities.  Full Article

Bluebird Bio enters into patent license agreement with Glaxosmithkline for commercialization of Gene Therapies
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Bluebird Bio Inc :Bluebird bio enters lentiviral vector patent license agreement with Glaxosmithkline for commercialization of gene therapies.Bluebird bio - under terms of agreement, gsk will non-exclusively license certain bluebird patent rights related to lentiviral vector technology.Bluebird bio- financial terms of agreement include an upfront payment to bluebird as well as potential development and regulatory milestone payments.Bluebird bio inc - financial terms of agreement also include low single digit royalties on net sales of covered products.  Full Article

Bluebird Bio entered into a worldwide license agreement around its proprietary lentiviral vector platform with Novartis Pharma
Tuesday, 2 May 2017 08:00am EDT 

May 2 (Reuters) - Bluebird Bio Inc :Bluebird bio inc- entered into a worldwide license agreement around its proprietary lentiviral vector platform with novartis pharma ag.Bluebird bio inc- financial terms of agreement with novartis include an upfront payment to bluebird as well as milestone and royalty payments.Bluebird bio-under terms novartis to non-exclusively license certain of co's patent rights to develop, commercialize chimeric antigen receptor t cell therapies for oncology.  Full Article

Bluebird bio qtrly net loss per share $1.88
Wednesday, 22 Feb 2017 04:05pm EST 

Bluebird Bio Inc : Bluebird Bio reports fourth quarter and full year 2016 financial results and recent operational progress . Bluebird Bio Inc - collaboration revenue was $1.6 million for Q4 of 2016 compared to $1.5 million . Bluebird Bio - expects cash, cash equivalents of $884.8 million as of Dec 31, 2016 to be sufficient to fund its current operations into H2 of 2019 .Bluebird Bio Inc qtrly net loss per share - basic and diluted $1.88.  Full Article

Bluebird Bio Inc commenced an underwritten public offering of $200 mln of its common stock
Tuesday, 6 Dec 2016 04:19pm EST 

Bluebird Bio Inc : Bluebird Bio Inc - has commenced an underwritten public offering of $200 million of its common stock .Bluebird bio announces proposed public offering of common stock.  Full Article

BRIEF-Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors

* Bluebird Bio appoints Mary Lynne Hedley, Ph.D. to board of directors Source text for Eikon: Further company coverage: